Key Developments: Medinet Co Ltd (2370.T)

2370.T on Tokyo Stock Exchange

236JPY
2:00am EDT
Price Change (% chg)

¥1 (+0.43%)
Prev Close
¥235
Open
¥237
Day's High
¥238
Day's Low
¥233
Volume
328,400
Avg. Vol
1,205,076
52-wk High
¥1,039
52-wk Low
¥230

Search Stocks

Latest Key Developments (Source: Significant Developments)

MEDINET forms strategic partnership with TC BioPharm
Tuesday, 11 Mar 2014 04:00am EDT 

MEDINET Co Ltd:Formed a strategic partnership on Feb. 21 with TC BioPharm Ltd., which is a Scottish start-up biotechnology company, to develop a immuno-cell medicinal product for cancer patients in the UK and Europe.MEDINET will finance TC BioPharm and will exclusively license TC BioPharm for use associated directly development and sales of MEDINET’s technology in this area.  Full Article

MEDINET Co Ltd announces extraordinary profit for Q2 of FY 2014
Wednesday, 5 Mar 2014 02:00am EST 

MEDINET Co Ltd:To record extraordinary profit of 440 million yen on selling of investment securities, for the second quarter of fiscal year ending Sep. 2014.  Full Article

MEDINET Co Ltd to dissolve China-based wholly owned subsidiary
Thursday, 27 Feb 2014 01:30am EST 

MEDINET Co Ltd:To dissolve a China-based wholly owned subsidiary, which has been engaged in biotechnology and medical equipment technology business, as well as drug and chemical import and export business.Liquidation to be completed in 2014.  Full Article

MEDINET Co Ltd to start clinical trial with University of Fukui and Seta Clinic Group
Thursday, 6 Feb 2014 01:00am EST 

MEDINET Co Ltd:Says it has decided to start clinical trial with University of Fukui and Seta Clinic Group regarding dendritic cell vaccine combined with transcatheter arterial embolization for patients with hepatocellular carcinoma.  Full Article

MEDINET Co Ltd enters into license agreement with Argos Therapeutics Inc
Friday, 10 Jan 2014 02:00am EST 

MEDINET Co Ltd:Says it entered into a license agreement with Argos Therapeutics Inc (Argos) on Dec, 27, 2013 in order to develop and commercialize AGS-003 as an immuno-cell medicinal product for metastatic renal cell cancer in Japan.Says Argos granted MEDINET an exclusive, royalty-free license to manufacture in Japan for the purpose of the development and commercialization of AGS-003 as well as an option to acquire a nonexclusive, royalty-bearing license to sell it in Japan.Says MEDINET paid Argos and loaned Argos in connection with Argos entering into the agreement.  Full Article

MEDINET Co Ltd completes share issuance
Thursday, 26 Dec 2013 01:00am EST 

MEDINET Co Ltd:Says it has completed to issue 9,000 shares to London Branch of Deutsche Bank, as well as 1,000 shares of YUME TECHNOLOGY CO LTD through private placement on Dec. 26.Says issue price at 43,695 yen per share, or net proceeds of 436,000,000 yen.  Full Article

MEDINET Co Ltd receives patent for DC activation method
Tuesday, 24 Dec 2013 01:00am EST 

MEDINET Co Ltd:Says it has received a patent for method for activation treatment of antigen-presenting cell in the United States, with patent number of 8609410.Says the activation method is for dendritic cell (DC) through induction of cytotoxic T lymphocyte (CTL).  Full Article

MEDINET Co Ltd to issue new shares
Thursday, 5 Dec 2013 02:30am EST 

MEDINET Co Ltd:Says it plans to issue 10,000 new shares through private placement to the London branch of Deutsche Bank (9,000 shares) and YUME TECHNOLOGY CO.,LTD. (1,000 shares).Says the shares issued at the price of 43,695 yen per share.Says to raise 436 million yen in total through the private placement.  Full Article

MEDINET Co Ltd to start new business
Thursday, 28 Nov 2013 02:30am EST 

MEDINET Co Ltd:Says it will establish a Tokyo-based wholly owned subsidiary, MEDcell Co., Ltd, in early Dec.Says it will start regenerative medicine product business through the subsidiary.Says the subsidiary will be engaged in the development, manufacturing, sale, export and import of regenerative medicine products.  Full Article

MEDINET Co Ltd to Split Stock; Announces Partial Change to Article of Incorporation of Authorized Share Number
Thursday, 24 Oct 2013 03:00am EDT 

MEDINET Co Ltd announced that it has decided to split one share of its common stock into 100 shares, effective April 1, 2014. After the stock splitting, the total share outstanding will become 87,333,100. The Company has received approval from the shareholders meeting to make partial change to its article of incorporation. Based on change to article six, the Company will increase total number of authorized shares from 1,751,200 shares to 175,120,000 shares.  Full Article

Search Stocks